IP Library Granted Patent US 7,510,873
Granted Patent B2
US 7,510,873 · App. 10/877,012 · Granted Mar 31, 2009

Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,510,873
App. No.
10/877,012
Granted
Mar 31, 2009
Kind
B2
Abstract

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

Claims (29)

1. An isolated cell, wherein said isolated cell is obtained by contacting mammalian umbilical cord tissue substantially free of blood with either dispase or dispase and at least one of hyaluronidase and collagenase and obtaining the cells yielded by said contacting step;

wherein said isolated cell self-renews and expands its numbers in culture;

wherein said isolated cell can differentiate into a cell that expresses markers indicative of differentiation into a type selected from the group consisting of neural cells, hepatocytes, adipocytes, pancreatic beta cells, chondrocytes, and cardiomyocytes;

and wherein said isolated cell does not express CD45 or CD117.

2. A cell culture comprising the isolated cell of claim 1 wherein said culture expands in the presence of about 5% to about 20% oxygen.

3. The isolated cell of claim 1 , wherein said isolated cell maintains a normal karyotype upon passaging.

4. The isolated cell of claim 1 wherein the isolated cell expresses one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, or HLA-A,B,C.

5. The isolated cell of claim 4 wherein the isolated cell expresses each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

6. The isolated cell of claim 1 wherein the isolated cell does not express one or more of CD31, CD34, CD141, or HLA-DR,DP,DQ, as detected by flow cytometry.

7. The isolated cell of claim 6 wherein the isolated cell expresses one or more of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, or HLA-A,B,C.

8. The isolated cell of claim 6 wherein the isolated cell does not express any of CD31, CD34, CD141, or HLA-DR,DP,DQ, as detected by flow cytometry.

9. The isolated cell of claim 8 wherein the isolated cell expresses each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C.

10. A conditioned medium made by culturing the isolated cell of claim 1 .

11. The conditioned medium of claim 10 comprising one or more of MCP- 1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, and TIMP1.

12. A culture comprising the isolated cell of claim 1 and a mammalian cell that is not the isolated cell of claim 1 .

13. The culture of claim 12 comprising a human cell line.

14. A three dimensional matrix comprising the isolated cell of claim 1 .

15. The three-dimensional matrix of claim 14 wherein the matrix comprises a biocompatible or bioabsorbable polymer.

16. The three-dimensional matrix of claim 15 wherein the matrix comprises a nonwoven mat comprising a copolymer of glycolic and lactic acids, PCL/PGA copolymer, or self assembling peptides.

17. The isolated cell of claim 1 wherein said isolated cell requires L-valine for growth.

18. The isolated cell of claim 17 which doubles sufficiently to generate yields of greater than about 10 14 cells in less than about 80 days in culture when seeded at about 10 3 cells/cm 2 .

19. The isolated cell of claim 17 which doubles sufficiently to generate greater than about 10 15 cells in less than about 80 days in culture when seeded at about 5 ×10 3 cells/cm 2 .

20. The isolated cell of claim 19 which doubles sufficiently to generate greater than about 10 17 cells in less than about 65 days in culture when seeded at about 5 ×10 3 cells/cm 2 .

21. The isolated cell of claim 1 which undergoes at least 40 doublings in culture.

22. The isolated cell of claim 1 , wherein said isolated cell is obtained from human umbilical cord tissue.

23. The isolated cell of claim 1 which attaches and doubles and expands when cultured on a coated or uncoated tissue culture vessel, wherein a coated tissue culture vessel comprises a coating with gelatin, laminin, collagen, polyornithine, polylysine, vitronectin, or fibronectin.

24. The cell culture of claim 2 , which expands in a culture medium comprising from about 2% to about 15% serum, with or without beta-mercaptoethanol, and with or without a growth factor selected from the group consisting of EGF, FGF, PDGF, VEGF, IGF, and LIF.

25. A homogeneous cell population comprising isolated cells of claim 1 .

26. The isolated cell of claim 1 wherein the collagenase is a collagenase from Clostridium histolyticum.

Assignments (9)
CHANGE OF NAME Recorded Nov 24, 2015
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 037156/0304 →
MERGER Recorded Mar 10, 2014
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: DEPUY ORTHOPAEDICS, INC.
Reel/Frame 032392/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: DEPUY ORTHOPAEDICS, INC.
To: DEPUY SPINE, INC.
Reel/Frame 032393/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS LLC
Reel/Frame 032393/0296 →
CHANGE OF NAME Recorded Mar 10, 2014
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 032422/0444 →
CHANGE OF NAME Recorded Mar 10, 2014
From: HAND INNOVATIONS LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 032422/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INCORPORATED
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026291/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2009
From: MISTRY, SANJAY; KIHM, ANTHONY J.; HARRIS, IAN R.; HARMON, ALEXANDER M.; SEYDA, AGNIESZKA; YI, CHIN-FENG; GOSIEWSKA, ANNA; MESSINA, DARIN J.
To: ETHICON, INCORPORATED
Reel/Frame 022285/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2004
From: MISTRY, SANJAY; KIHM, ANTHONY J.; HARRIS, IAN ROSS; HARMON, ALEXANDER M.; MESSINA, DARIN J.; SEYDA, AGNESZKA; YU, CHIN-FENG; GOSIEWSKA, ANNA
To: ETHICON, INCORPORATED
Reel/Frame 015391/0354 →